Semaglutide·Novo Nordisk·Injectable pen

Wegovy

Wegovy is a once-weekly injectable semaglutide pen manufactured by Novo Nordisk, FDA-approved in June 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It is the first semaglutide product approved explicitly for weight loss and delivers the highest approved semaglutide dose at 2.4mg. In the landmark STEP clinical trial program, Wegovy demonstrated average weight loss of 15-17% of body weight, establishing it as one of the most effective anti-obesity medications available. At Weight Method, Wegovy-equivalent semaglutide treatment starts at $297/month.

0.25mg0.5mg1mg1.7mg2.4mgOnce weekly
Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Wegovy is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated March 2026Medically reviewed by licensed providers

Wegovy (semaglutide) is an FDA-approved GLP-1 medication for weight loss. In clinical trials, patients lost an average of 15-22% of their body weight. Weight Method offers Wegovy starting at $297/month with virtual consultations and direct shipping.

Key Fact

Wegovy (semaglutide 2.4mg) is the first GLP-1 medication FDA-approved specifically for chronic weight management (June 2021). STEP 1 trial: 14.9% average body weight loss over 68 weeks. Retail: ~$1,349/month. Weight Method semaglutide: $297/month.

Source: STEP 1 Trial — Wilding et al., NEJM 2021

How does this medication work?

Wegovy (semaglutide 2.4mg) activates GLP-1 receptors in the brain to suppress hunger, reduce cravings, and slow digestion — delivering 15-17% average body weight loss.

Wegovy works by activating GLP-1 receptors throughout the body, primarily in the brain's appetite-regulation centers. The semaglutide in Wegovy mimics the natural GLP-1 hormone, reducing hunger signals, increasing feelings of fullness, and decreasing food cravings -- including cravings for high-fat and high-sugar foods. It also slows gastric emptying to extend satiety after meals. At the 2.4mg maintenance dose, Wegovy provides a stronger appetite-suppressing effect than lower-dose semaglutide formulations like Ozempic, which contributes to its superior weight loss outcomes in clinical trials.

What is it FDA-approved for?

FDA-approved for chronic weight management (2021) and cardiovascular risk reduction (2024). The first semaglutide product with an explicit anti-obesity indication.

Wegovy is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. In March 2024, the FDA also approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight, making it the first anti-obesity medication with a cardiovascular risk reduction indication.

What are the key facts you should know?

Once-weekly injection, 2.4mg maintenance dose, 16-20 week dose escalation, STEP trial showed 14.9% weight loss, manufactured by Novo Nordisk.

Wegovy is available in five dose strengths -- 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg -- following a structured 16-20 week dose-escalation schedule to the maintenance dose of 2.4mg once weekly. In the STEP 1 trial, participants taking Wegovy 2.4mg lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo. Approximately one-third of STEP 1 participants lost 20% or more of their body weight. The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major adverse cardiovascular events.

Why choose this treatment?

Wegovy delivers the highest approved semaglutide dose with the strongest clinical weight loss data, plus a unique cardiovascular risk reduction benefit from the SELECT trial.

Wegovy is the ideal choice for patients whose primary goal is significant, sustained weight loss under an FDA-approved indication. Its 2.4mg maintenance dose delivers the strongest semaglutide effect available, and the STEP trial data provides robust clinical evidence for its efficacy. The added cardiovascular benefit makes it particularly compelling for patients with heart disease risk factors. Weight Method offers Wegovy-equivalent semaglutide at $297/month -- a fraction of the $1,300+/month retail price -- with full provider support and free home delivery.

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Clinically proven GLP-1 medications at transparent prices

Starting at$297/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Same active ingredient as Ozempic® & Wegovy®. Proven to reduce body weight by up to 15%.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Same active ingredient as Mounjaro® & Zepbound®. Dual-action GLP-1/GIP for enhanced results.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Wegovy and Ozempic both contain semaglutide, but Wegovy is FDA-approved specifically for weight loss at a higher maximum dose (2.4mg vs. 2mg). Wegovy's dosing schedule is also designed to reach higher therapeutic levels for appetite suppression. In clinical trials, patients on Wegovy's 2.4mg dose achieved greater average weight loss than those on Ozempic's diabetes-focused dosing.

The STEP 1 clinical trial showed average weight loss of 14.9% of body weight over 68 weeks with Wegovy 2.4mg. About one-third of participants lost 20% or more. In real-world practice, results typically range from 15-17% of body weight over 12-18 months. Your individual results will depend on adherence, starting weight, diet, and activity level.

Yes. The SELECT trial demonstrated that Wegovy reduced the risk of major adverse cardiovascular events -- including heart attack, stroke, and cardiovascular death -- by 20% in adults with established cardiovascular disease and obesity. In March 2024, the FDA added this cardiovascular risk reduction to Wegovy's approved labeling, making it the first weight-loss medication with this indication.

Wegovy follows a gradual dose-escalation schedule over 16-20 weeks: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, then the maintenance dose of 2.4mg. This slow ramp-up minimizes gastrointestinal side effects and allows your body to adjust to the medication. Your Weight Method provider may adjust the timeline based on your tolerability.

The most common side effects are nausea, diarrhea, vomiting, constipation, and abdominal pain, primarily during dose escalation. In STEP trials, approximately 44% of participants reported nausea, though most cases were mild to moderate and resolved within weeks. Serious but rare side effects include pancreatitis, gallbladder problems, and allergic reactions. Your Weight Method provider monitors your progress to manage any side effects proactively.

Weight Method offers semaglutide treatment at $297/month -- no insurance required. Brand-name Wegovy retails for over $1,300/month at traditional pharmacies without insurance. Weight Method's pricing includes your medication, licensed provider consultations, dosing management, and free home delivery.

Yes, Wegovy requires a prescription from a licensed healthcare provider. At Weight Method, the process is streamlined: complete a free online quiz, receive a medical evaluation from a licensed provider, and if eligible, your prescription and medication are shipped directly to your home. No office visits or waiting rooms required.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

More about Wegovy

Wegovy Side EffectsWegovy ResultsWegovy Dosingsemaglutide Dosage Calculator

Generic Medication

Semaglutide

Other Semaglutide Brands

OzempicRybelsusOral WegovySemaglutide

Compare Wegovy

Ozempic vs WegovyWegovy vs ZepboundWegovy vs MounjaroOral Wegovy vs Wegovy

Wegovy by State

Wegovy in AlabamaWegovy in AlaskaWegovy in ArizonaWegovy in ArkansasWegovy in CaliforniaWegovy in Colorado